Adherence to a treat-to-target strategy in early rheumatoid arthritis: Results of the DREAM remission induction cohort

Arthritis Research and Therapy

Volumn 14, Issue 6, 2012, Pages

  Vermeer, Marloes ^a,b   Kuper, Hillechiena H ^b   Bernelot Moens, Hein J ^c   Hoekstra, Monique ^d   Posthumus, Marcel D ^e   van Riel, Piet L C M ^f   van de Laar, Mart A F J ^a,b  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c TWENTEBORG HOSPITAL   (Netherlands)

^d Department of Rheumatology Isala Klinieken ^*  (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE REDUCTION; FEMALE; HAIR LOSS; HEMATOLOGIC DISEASE; HUMAN; LIVER FUNCTION TEST; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL FUNCTION; MOOD CHANGE; NAUSEA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SCORING SYSTEM; SIDE EFFECT; TREATMENT PLANNING; TREATMENT TO TARGET; VISUAL DISORDER; AGED; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; COHORT ANALYSIS; DRUG COMBINATION; EARLY DIAGNOSIS; FOLLOW UP; MIDDLE AGED; NETHERLANDS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROCEDURES; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

ABDOMINAL PAIN; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; NAUSEA; NETHERLANDS; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SULFASALAZINE;

EID: 84869888155     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4099     Document Type: Article

References (39)

1. Klarenbeek NB, Allaart CF, Kerstens PJ, Huizinga TW, Dijkmans BA. The BeSt story: on strategy trials in rheumatoid arthritis. Curr Opin Rheumatol 2009, 21:291-298. 10.1097/BOR.0b013e32832a2f1c, 19318946.
2. McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010, 69:1898-1906. 10.1136/ard.2010.134684, 20959326.
3. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975. 10.1136/ard.2009.126532, 2935329, 20444750.
4. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004, 364:263-269. 10.1016/S0140-6736(04)16676-2, 15262104.
5. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, Blaauw AA, Bijlsma JW. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007, 66:1443-1449. 10.1136/ard.2007.071092, 2111604, 17519278.
6. Fransen J, Moens HB, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005, 64:1294-1298. 10.1136/ard.2004.030924, 1755664, 15829574.
7. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van Schaardenburg D, Speyer I, Seys PE, Breedveld FC, Allaart CF, Dijkmans BA. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2010, 69:65-69. 10.1136/ard.2008.097683, 19155234.
8. Schipper L, Vermeer M, Kuper H, Hoekstra M, Haagsma C, den Broeder A, van Riel P, Fransen F, van de Laar M. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2012, 71:845-850. 10.1136/annrheumdis-2011-200274, 22210852.
9. Schipper LG, van Hulst LT, Grol R, van Riel PL, Hulscher ME, Fransen J. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford) 2010, 49:2154-2164.
10. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002, 46:328-346. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines.
11. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D, . T2T Expert Committee Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637. 10.1136/ard.2009.123919, 3015099, 20215140, T2T Expert Committee.
12. Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, Da Silva JP, de Wit M, Dougados M, Durez P, Emery P, Fonseca JE, Gibofsky A, Gomez-Reino J, Graninger W, Hamuryudan V, Jannaut Peña MJ, Kalden J, Kvien TK, Laurindo I, Martin-Mola E, Montecucco C, Santos Moreno P, Pavelka K, Poor G, Cardiel MH, Stanislawska-Biernat E, Takeuchi T, van der Heijde D, . Treat to Target Taskforce Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. Ann Rheum Dis 2011, 70:1999-2002. 10.1136/ard.2011.154179, 3273732, 21803747, Treat to Target Taskforce.
13. van Hulst LT, Creemers MC, Fransen J, Li LC, Grol R, Hulscher ME, van Riel PL. How to improve DAS28 use in daily clinical practice?--a pilot study of a nurse-led intervention. Rheumatology (Oxford) 2010, 49:741-748.
14. Littlejohn G, Tymms KE. Multi-centre, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control. Arthritis Rheum 2010, 62(Suppl 10):320.
15. Tymms K, Littlejohn G. The MDA study - a multi-centre, cross-sectional, study of barriers to optimal control for rheumatoid arthritis patients with moderate and high disease activity. Ann Rheum Dis 2011, 70(Suppl 3):76.
16. Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 2005, 53:241-248. 10.1002/art.21077, 15818655.
17. Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, De Gendt CM, Ronday KH, Jansen TL, van Oijen PC, Brus HL, Adang EM, van Riel PL. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007, 66:1473-1478. 10.1136/ard.2007.072447, 2111629, 17426065.
18. Verschueren P, Westhovens R. Optimal care for early RA patients: the challenge of translating scientific data into clinical practice. Rheumatology (Oxford) 2011, 50:1194-1200.
19. Harrold LR, Harrington JT, Curtis JR, Furst DE, Bentley MJ, Shan Y, Reed G, Kremer J, Greenberg JD. Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. Arthritis Rheum 2012, 64:630-638. 10.1002/art.33380, 21953645.
20. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 2003, 30:1138-1146.
21. Hoekstra M, van de Laar MA, Bernelot Moens HJ, Kruijsen MW, Haagsma CJ. Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis. J Rheumatol 2003, 30:2325-2329.
22. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
23. Vermeer M, Kuper HH, Hoekstra M, Haagsma CJ, Posthumus MD, Brus HL, van Riel PL, van de Laar MA. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum 2011, 63:2865-2872. 10.1002/art.30494, 21647867.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
25. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137-145. 10.1002/art.1780230202, 7362664.
26. Siegert CE, Vleming LJ, Vandenbroucke JP, Cats A. Measurement of disability in Dutch rheumatoid arthritis patients. Clin Rheumatol 1984, 3:305-309. 10.1007/BF02032335, 6488708.
27. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483. 10.1097/00005650-199206000-00002, 1593914.
28. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewé R, Listing J, Michaud K, Martin-Mola E, Montie P, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011, 70:404-413. 10.1136/ard.2011.149765, 21292833.
29. Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010, 62:857-864.
30. Khan NA, Spencer HJ, Abda E, Aggarwal A, Alten R, Ancuta C, Andersone D, Bergman M, Craig-Muller J, Detert J, Georgescu L, Gossec L, Hamoud H, Jacobs JW, Laurindo IM, Majdan M, Naranjo A, Pandya S, Pohl C, Schett G, Selim ZI, Toloza S, Yamanaka H, Sokka T. Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 2012, 64:206-214.
31. van Hulst LT, Kievit W, van Bommel R, van Riel PL, Fraenkel L. Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment. Arthritis Care Res (Hoboken) 2011, 63:1407-1414.
32. Wolfe F, Michaud K. Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. Arthritis Rheum 2007, 56:2135-2142. 10.1002/art.22719, 17599730.
33. van der Leeden M, Steultjens MP, van Schaardenburg D, Dekker J. Forefoot disease activity in rheumatoid arthritis patients in remission: results of a cohort study. Arthritis Res Ther 2010, 12:R3. 10.1186/ar2901, 2875628, 20055986.
34. Makinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?. Ann Rheum Dis 2005, 64:1410-1413. 10.1136/ard.2005.037333, 1755218, 15941836.
35. Landewe R, van der Heijde D, van der Linden S, Boers M. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 2006, 65:637-641. 10.1136/ard.2005.039859, 1798155, 16219709.
36. Taylor WJ, Harrison AA, Highton J, Chapman P, Stamp L, Dockerty J, McQueen F, Jones PB, Ching D, Porter D, Rajapakse C, Rudge SR, Taylor G, Kumar S, Macedo T, Hoy MS. Disease Activity Score 28-ESR bears a similar relationship to treatment decisions across different rheumatologists, but misclassification is too frequent to replace physician judgement. Rheumatology (Oxford) 2008, 47:514-518.
37. Lindsay K, Ibrahim G, Sokoll K, Tripathi M, Melsom RD, Helliwell PS. The composite DAS Score is impractical to use in daily practice: evidence that physicians use the objective component of the DAS in decision making. J Clin Rheumatol 2009, 15:223-225. 10.1097/RHU.0b013e3181b126b1, 19590441.
38. Kievit W, van Hulst L, van Riel P, Fraenkel L. Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis. Arthritis Care Res (Hoboken) 2010, 62:842-847.
39. Blom M, Kievit W, Kuper HH, Jansen TL, Visser H, den Broeder AA, Brus HL, van de Laar MA, van Riel PL. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res (Hoboken) 2010, 62:1335-1341.